Stanford Radiology to Collaborate with Novartis to Advance Innovation in Translational Imaging Research

STANFORD, CALIF. – December 17, 2025 – The Stanford Medicine Department of Radiology is proud to announce its participation in an academic-industry collaboration with Novartis designed to accelerate translational research and develop early evidence around targets for radioligand imaging (RLI) across a wide range of oncological applications.

Through this collaboration, Stanford Radiology will contribute its world-class expertise in molecular imaging, nuclear medicine, and translational medicine to help inform RLI strategies as a guide to various therapeutic areas.

“We are excited to leverage the Novartis pipeline to help potentially translate promising preclinical targets into effective radioligand imaging for patient care, through innovative research collaborations” said Dr. Andrei Iagaru, Professor of Radiology, Nuclear Medicine.

“As an institution committed to advancing the frontiers of medical imaging and patient care, the Department of Radiology is excited to participate in an initiative that fosters agile, collaborative science,” said Dr. Quynh-Thu Le, interim Chair of the Department of Radiology. “We look forward to helping shape the next generation of imaging tools that support precision medicine and accelerate the clinical development of radioligand imaging and potentially therapies.”

“The project we’ve proposed for this collaboration will allow us to explore and potentially validate imaging technologies that support early clinical decision-making,” added Dr. Erin Grady, interim Chief of the Division of Nuclear Medicine and Molecular Imaging.

Stanford Radiology’s involvement in this initiative reflects a broader commitment to fostering dynamic collaborations between academia and industry to improve health outcomes through cutting-edge research.

For more information about Stanford Radiology’s research initiatives, please visit radiology.stanford.edu and visit our LinkedIn page.